



From Nature for Life

PRESS RELEASE

Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025

- **Withdrawal of the convocation request as of 1 August 2025 by Grifols S.A.**

Dreieich, 23 October 2025. Biotest AG hereby announces that its majority shareholder, Grifols S.A., Barcelona, Spain, informed the Management Board on 22 October 2025 that it is withdrawing from the request as of 1 August 2025 to convene an extraordinary general meeting. In the same letter, Grifols S.A. also requested the convening of an extraordinary general meeting to resolve on the change of legal form of Biotest AG from a stock corporation (Aktiengesellschaft, AG) into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA). The Supervisory Board was immediately informed of the receipt of this request.

The Management Board with the approval of the Supervisory Board decided to cancel the extraordinary general meeting scheduled for 28 October 2025.

The Management Board will carefully review the new request of Grifols S.A. to convene an extraordinary general meeting to resolve on the change of legal form of the company into a partnership limited by shares (KGaA), pursuant to Section 122 (1) of the German Stock Corporation Act (AktG). If the new request for convocation is admissible, the Management Board will invite again to an extraordinary general meeting. The details will be published by the company.

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,500 employees worldwide. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Baumann (Buttkereit)
Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Miriam Oehme
Phone: +49 -152 07016 992
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biostest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.